PATENT CLAIM ANALYSIS

Application Number: 16001514
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "423000"]

Abstract:
Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices

Claim (Index 38):
The composition of  claim 34 , wherein the water-insoluble therapeutic agent is selected from the group consisting of paclitaxel, docetaxel, a paclitaxel analog, or a paclitaxel derivative or other taxane compound; a macrolide immunosuppressive agent such as sirolimus (rapamycin), pimecrolimus, tacrolimus, everolimus, zotarolimus, novolimus, myolimus, temsirolimus, deforolimus, or biolimus; an antiproliferative agent; a smooth muscle cell inhibitor; and an inhibitor of the mammalian target of rapamycin (mTOR inhibitor)

Metadata:
- Claim Count in Document: 2.0
- Percentile: 94.0
- Lexical Diversity: 1.37037
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15386662', '14880332', '14454325', '15496466', '14454345']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8242208299369278
- 35 USC 102 Novelty (BERT): 0.5948221622992461
- Combined Prediction Score: 0.8012809631731597
- Mean Citation Score: 462.74375
- Max Citation Score: 552.79346
- Similarity Product: 369.2887895896232

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test